We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.
One such company that might be well-positioned for future earnings growth is LeMaitre Vascular, Inc. (LMAT - Free Report) . This firm, which is in the Medical Products, saw EPS growth of 61.5% last year, and is looking great for this year too.
In fact, the current growth estimate for this year calls for earnings-per-share growth of 35.7%. Furthermore, the long-term growth rate is currently an impressive 15%, suggesting pretty good prospects for the long haul.
And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 3.6%. Thanks to this rise in earnings estimates, LMAT has a Zacks Rank #2 (Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
So if you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider LMAT. Not only does it have double digit earnings growth prospect, but its impressive Zacks Rank suggests that analysts believe better days are ahead for LMAT as well.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is LeMaitre Vascular (LMAT) Great Growth Stock?
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.
One such company that might be well-positioned for future earnings growth is LeMaitre Vascular, Inc. (LMAT - Free Report) . This firm, which is in the Medical Products, saw EPS growth of 61.5% last year, and is looking great for this year too.
In fact, the current growth estimate for this year calls for earnings-per-share growth of 35.7%. Furthermore, the long-term growth rate is currently an impressive 15%, suggesting pretty good prospects for the long haul.
LEMAITRE VASCLR Price and Consensus
LEMAITRE VASCLR Price and Consensus | LEMAITRE VASCLR Quote
And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 3.6%. Thanks to this rise in earnings estimates, LMAT has a Zacks Rank #2 (Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
So if you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider LMAT. Not only does it have double digit earnings growth prospect, but its impressive Zacks Rank suggests that analysts believe better days are ahead for LMAT as well.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>